TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06854640: First in Patient, Dose Escalation, Open Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusion of BAY 3389934 to Patients With Sepsis Induced Coagulopathy

Sponsor: Bayer · Phase: PHASE1 · Area: INFECTIOUS_VACCINE · Target Enrollment: 36 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$239,904

Rescue Site Savings

+$159,936

Unlock Full NCT06854640 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06854640 Rescue Dossier →